|
Sep 30
|
High Growth Tech Stocks To Watch For Future Potential
|
|
Sep 25
|
Incyte Gains 12.7% Year to Date: How Should You Play the Stock?
|
|
Sep 25
|
Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress
|
|
Sep 6
|
Allogene Therapeutics (ALLO) Up 6.4% Since Last Earnings Report: Can It Continue?
|
|
Aug 30
|
Why Is Glaxo (GSK) Up 10.3% Since Last Earnings Report?
|
|
Aug 29
|
Incyte (INCY) Up 0.9% Since Last Earnings Report: Can It Continue?
|
|
Aug 27
|
Exploring Three High Growth Tech Stocks In The United States
|
|
Aug 21
|
Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz®) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024
|
|
Aug 16
|
Armed with Phase III win, Incyte eyes label expansion for Monjuvi
|
|
Jul 24
|
Is a Beat in the Cards for Incyte (INCY) in Q2 Earnings?
|
|
Jul 24
|
Qiagen (QGEN) Expected to Beat Earnings Estimates: Should You Buy?
|
|
Jul 23
|
Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth
|
|
Jul 10
|
Company News for July 10, 2024
|
|
Jul 9
|
Incyte to Report Second Quarter Financial Results
|
|
Jul 8
|
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Jun 14
|
Insider Sale: EVP & General Manager US Barry Flannelly Sells 19,164 Shares of Incyte Corp (INCY)
|
|
Jun 13
|
Incyte Announces Final Results of Tender Offer
|
|
Jun 11
|
Incyte Announces Preliminary Results of Tender Offer
|
|
May 14
|
Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress
|
|
May 14
|
Company News For May 14, 2024
|